CTOs on the Move

EmCare Holdings

www.emcare.com

 
EmCare Holdings Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. EmCare Holdings Inc. is based in Dallas, TX. You can find more information on EmCare Holdings Inc. at www.emcare.com
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.emcare.com
  • 13737 Noel Rd Suite 1600
    Dallas, TX USA 75240
  • Phone: 214.712.2000

Executives

Name Title Contact Details

Similar Companies

Care Alternatives

Care Alternatives is a Cranford, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Good360

Good360 is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EyeQue

We are dedicated to creating affordable, accessible, and accurate eye care solutions specifically for you and your family. Our founders bring patents from MIT and decades of eye care industry experience to create innovative eye care products that can be used in our every day lives. The traditional eye care system hasnt changed in decades, but our advanced optical technology combined with the modern capabilities of smartphones, have shaped a new avenue of health technology - at home vision testing.

Arbor House Assisted Living

Arbor House Assisted Living is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProKidney

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III